SLC2A1 and Dravet syndrome: The model results offer a new take on the therapeutic mechanism of the KD, which is thought to be effective for GLUT1-DS because it supplies ketone bodies as energy to the brain and has antiepileptic properties [31] (Klepper et al., 2020).